Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Expert Opinion on Drug Safety|December 9, 2010
Reviewing the safety of erlotinib in non-small cell lung cancerMartin Reck, Tony Mok, Jürgen Wolf, et al.Onkologie|October 10, 2009
Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphomaAndreas Engert, Auro del Giglio, Peter Bias, et al.Clinical Lung Cancer|July 6, 2011
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based reviewAlex A Adjei, George R Blumenschein, Sumithra Mandrekar, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment studyMartin Reck, Nico van Zandwijk, Cesare Gridelli, et al.Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.Medizinische Klinik, Intensivmedizin Und Notfallmedizin|June 24, 2026
[Invasive mechanical ventilation: indications and alternatives : Systematic evaluation of the evidence and recommendations for clinical practice from the S3 guidelines "invasive mechanical ventilation and the use of extracorporeal procedures in acute respiratory failure"]Margarethe Grupp, Patrick Schramm, Nora Bruns, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 26, 2012
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancerSylvia K Haas, Mathias Freund, David Heigener, et al.Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST studyClaus-Peter Schneider, David Heigener, Kathrin Schott-von-Römer, et al.Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.Pageof 4